Company Overview
XBiotech Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where it discovers and develops True Human monoclonal antibodies designed to treat various diseases. The company maintains a development pipeline of product candidates that target inflammatory and infectious diseases, alongside ongoing work on interleukin-1 alpha therapies for multiple medical conditions. This biopharmaceutical entity employs a workforce of 85 individuals to support its research and development objectives. With a market capitalization of $69.21M, the company represents a small-cap profile typical for early-stage biotechnology firms that are still generating negative net income of $-45,540,000. The absence of reported annual revenue alongside a market cap of $69.21M indicates that the company is likely in a pre-commercialization or late-stage development phase where value is derived from pipeline potential rather than current sales volume. This specific financial position suggests the enterprise is allocating its resources toward long-term product candidates rather than immediate profit generation. The employee count of 85 further contextualizes the scale, indicating a lean organizational structure common in the biotech sector where capital is concentrated on high-value intellectual property and clinical trials.
Financial Health
The company reports a net income of $-45,540,000 and an EBITDA of $-53,999,000 over the trailing twelve months, while revenue figures are not available for calculation. The significant gap between revenue and net income, combined with the reported zero gross margin, reveals a cost structure dominated by research and development expenditures that have not yet been offset by product sales. Free cash flow stands at $-26,277,124, which indicates that the company is currently consuming cash to fund its operations and development activities rather than generating surplus liquidity. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, which reflects a standard characteristic for biotechnology companies that have not yet achieved commercial revenue or are operating at a loss to fund their pipelines. Total cash holdings amount to $125.55M, providing a substantial buffer against the reported debt, which is listed as N/A and implies no significant leverage or that debt is negligible compared to cash reserves. The current ratio is reported at 16.01, a figure that indicates exceptional short-term liquidity and a robust ability to meet obligations with its available cash resources. Return on Equity is -28.2% and Return on Assets is -19.9%, metrics that reveal management is currently deploying capital to generate losses typical of the biotechnology lifecycle rather than immediate returns on invested equity or assets.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of net income, whereas the forward P/E is listed at 17.46, implying that the market prices the stock based on projected future earnings rather than historical performance. The price-to-book ratio is 0.49, which indicates that the market is valuing the company at less than its net asset value, suggesting the stock trades at a discount relative to its book value. The price-to-sales ratio is N/A because revenue data is unavailable, and the enterprise value to EBITDA multiple is 1.04, which serves as an alternative valuation metric for companies with negative earnings or missing revenue data. The 52-week trading range spans from a low of $2.09 to a high of $3.62, and without a specific current price to calculate the exact percentage deviation, the valuation metrics suggest the stock is priced within a relatively narrow band relative to its historical volatility. The beta value is 0.89, indicating that the stock's price volatility is slightly lower than the broader market benchmark, suggesting it may be less sensitive to general market fluctuations than the average large-cap stock.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue due to the absence of comparable period data. The dividend yield is N/A and the payout ratio is 0.0%, which indicates that the company does not distribute dividends to shareholders. Given the negative net income and zero payout ratio, the company reinvests all available earnings, or rather its operating cash flow, back into research and development activities rather than paying out income to investors. The overall growth and income profile is characterized by a complete lack of current dividend income and undefined growth rates due to the company's status as a cash-consuming biopharmaceutical entity with no current commercial revenue stream.